CLA After 40: Does Conjugated Linoleic Acid Help Midlife Body Composition?
After 40, many people notice that body fat accumulates more easily, especially around the waist, while muscle becomes harder to maintain. Conjugated linoleic acid, or CLA, is often marketed to exactly this audience. Our editorial team looked at what the research shows for middle-aged adults and where the risks lie.
What CLA is
Conjugated linoleic acid refers to a group of isomers of linoleic acid, an omega-6 fatty acid. The two most studied isomers are cis-9, trans-11 and trans-10, cis-12. They differ only in the position and geometry of double bonds but behave quite differently in the body.
Natural CLA is found in small amounts in beef, lamb and dairy fat, mostly as the cis-9, trans-11 isomer. Grass-fed animals tend to produce more.
Supplements are made chemically from safflower or sunflower oil and usually contain roughly equal amounts of the two main isomers. This matters because the trans-10, cis-12 isomer is responsible for most of the fat-loss effect seen in animals and for some of the safety concerns.
CLA is sold as a dietary supplement in the US, and certain CLA preparations have GRAS (generally recognized as safe) status for use in specific foods.
Why midlife changes body composition
Several factors make body composition harder to control after 40. Resting metabolic rate declines modestly, partly due to loss of muscle mass. Physical activity often decreases with work and family demands.
Hormonal changes also play a role. In women, the menopausal transition shifts fat storage toward the abdomen. In men, testosterone gradually declines with age, though the drop is usually gradual in healthy men.
Insulin sensitivity tends to decline as well, which can make fat loss more difficult and increase cardiometabolic risk.
These changes are not inevitable. Resistance training, adequate protein and sleep can offset much of the decline, which is important context when evaluating any supplement.
What the research shows for fat loss
In mice, CLA produces dramatic fat loss. In humans, the effect is much smaller. A meta-analysis by Whigham and colleagues estimated that CLA at about 3.2 g per day reduced body fat by roughly 0.09 kg per week compared with placebo.
A later meta-analysis by Onakpoya and colleagues concluded that the effect on body weight was small and of uncertain clinical relevance.
| Outcome | Typical finding in trials | Clinical relevance |
|---|---|---|
| Body fat | Small reduction over months | Modest at best |
| Body weight | Little or no change | Low |
| Lean mass | Inconsistent, small changes | Uncertain |
| Waist circumference | Mixed results | Uncertain |
Few trials focused specifically on people over 40, and those that did often included participants with overweight or obesity. Results in this group are similar: small effects, if any.
Compared with consistent resistance training and modest calorie reduction, CLA's contribution is minor.
Safety concerns relevant after 40
Several concerns are particularly important for middle-aged adults, who are more likely to have cardiometabolic risk factors.
- Insulin sensitivity: some trials, particularly with the trans-10, cis-12 isomer, found reduced insulin sensitivity in men with abdominal obesity, a group already at risk for type 2 diabetes.
- Blood lipids: some studies reported decreased HDL cholesterol or increased markers of inflammation such as C-reactive protein.
- Liver fat: animal studies have shown fatty liver with high CLA intake; human data are limited.
- Digestive side effects: stomach upset, nausea and loose stools are commonly reported.
These findings are not consistent across all studies, and many trials found no significant harm. However, a supplement with small benefits and possible metabolic downsides deserves careful thought in people already at risk.
People with diabetes, prediabetes, fatty liver disease or cardiovascular disease should talk to their physician before considering CLA.
CLA may also interact with blood-thinning medications, so anyone on anticoagulants should seek medical advice.
If you still want to try CLA
Most human studies used about 3–4 g per day of mixed CLA isomers, taken with meals, for periods ranging from 12 weeks to a year.
Check the label for total CLA content per serving and isomer composition. Products should list grams of CLA rather than grams of oil.
Consider baseline blood tests such as fasting glucose, lipid profile and liver enzymes, and repeat them after a few months if you are in a higher-risk group.
Choose products that are third-party tested, such as USP Verified or NSF certified. CLA is not on the WADA Prohibited List.
Editorial team conclusions
CLA produces, at best, small reductions in body fat in humans, and the effect appears similar for people over 40.
Some studies suggest potential downsides for insulin sensitivity and blood lipids, which are especially relevant in middle age.
Resistance training, adequate protein, sleep and moderate calorie control offer far greater benefits for midlife body composition.
You may also want to read our articles on resistance training after 40, protein needs for older adults, and how to interpret metabolic blood tests.
References
- Whigham LD, Watras AC, Schoeller DA. Efficacy of conjugated linoleic acid for reducing fat mass: a meta-analysis in humans. Am J Clin Nutr. 2007;85(5):1203–1211.
- Onakpoya IJ, Posadzki PP, Watson LK, et al. The efficacy of long-term conjugated linoleic acid (CLA) supplementation on body composition in overweight and obese individuals: a systematic review and meta-analysis of randomized clinical trials. Eur J Nutr. 2012;51(2):127–134.
- Risérus U, Arner P, Brismar K, Vessby B. Treatment with dietary trans10cis12 conjugated linoleic acid causes isomer-specific insulin resistance in obese men with the metabolic syndrome. Diabetes Care. 2002;25(9):1516–1521.
- Gaullier JM, Halse J, Høye K, et al. Conjugated linoleic acid supplementation for 1 y reduces body fat mass in healthy overweight humans. Am J Clin Nutr. 2004;79(6):1118–1125.
- Wang YW, Jones PJ. Dietary conjugated linoleic acid and body composition. Am J Clin Nutr. 2004;79(6 Suppl):1153S–1158S.
- Cruz-Jentoft AJ, Bahat G, Bauer J, et al. Sarcopenia: revised European consensus on definition and diagnosis. Age Ageing. 2019;48(1):16–31.
